Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 34

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 34
---
 a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities
in the normal course of business. As at December 31, 2023 and June 30, 3024, we had cash and cash equivalents of £5.97 million and
£5.06 million, respectively.

We have prepared cash flow
forecasts and considered the cash flow requirement for the next three years, including the period 12 months from the date of approval
of the financial statements included in this prospectus. Our forecasts show that further financing will be required before the end of
the first quarter of 2025.

Our forecast of the period
of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks
and uncertainties, and actual results could vary as a result of a number of factors, including the timing of clinical trials. We have
based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently
expect. If we lack sufficient capital to expand our operations or otherwise capitalize on our business opportunities, our business, financial
condition and results of operations could be materially adversely affected.

| 17 |

If we raise additional funds
through the issuance of debt securities or additional equity securities, it could result in dilution to our existing shareholders, increased
fixed payment obligations and these securities may have rights senior to those of our ordinary shares (including the Depositary Shares)
and could contain covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our
ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating
restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business,
financial condition and prospects.

We believe the environment
for financing of small and micro-cap biotech companies remains challenging. While this may present acquisition and/or merger opportunities
with other companies with limited or no access to financing, any attendant financing is likely to be dilutive. We and our advisors
continue to evaluate financing options, including those connected to acquisitions and/or mergers, potentially available to us, including
fundraising and the partnering of assets and technologies of the Company. There can be no assurance that any of the courses of action
to finance the Company, will be successful. This requirement for additional financing in the short term represents a material uncertainty
that may cast doubt upon our ability to continue as